CIBMTR at 2026 ASH Annual Meeting
CIBMTR will have an outstanding presence at the 2026 American Society of Hematology (ASH) Annual Meeting, with 27 accepted abstracts: 14 oral presentations and 13 posters. These abstracts represent the work of 298 authors from 85 institutions. Of the 26 different presenting authors, 17 are junior including 2 fellows and 2 research scientists/post-docs. Together, these presentations showcase the breadth and impact of CIBMTR research and its potential to advance care across hematology and cellular therapy.
Beyond the numbers, this year’s presentations tell a broader story about CIBMTR’s role in generating evidence that can expand access to treatment, improve the safety and precision of cell therapy, and answer questions that require large-scale clinical trials, registry data, and collaborative science.
Expanding donor options
Several studies address one of the field’s most important challenges: helping more patients proceed to transplant when a fully matched donor does not exist.
Results from the ACCESS trial continue to build evidence supporting mismatched unrelated donor transplantation with post-transplant cyclophosphamide (PTCy). Two-year findings show outcomes that were broadly comparable with those observed in a major matched-donor trial, despite ACCESS enrolling patients receiving mismatched unrelated donor transplants and a larger proportion of patients that were ethnically diverse. Another ACCESS analysis found that patients had similar longer-term quality-of-life trajectories compared with matched-donor and real-world cohorts, even when early physical recovery was slower.
A related CIBMTR registry or observational analysis examined whether the specific HLA locus involved in a 7/8 donor mismatch affected outcomes. The results found no meaningful differences by mismatched locus, suggesting that clinicians may be able to place greater emphasis on factors such as younger donor age when choosing among available mismatched unrelated donors.
Why it matters: Together, these findings support a less restrictive approach to donor selection. This could allow more patients, including those less likely to identify a fully matched donor, many of whom are racially and ethnically diverse, to move forward with transplantation using the best available donor.
Making transplantation safer and more precise
Expanding access is only part of the goal. Other CIBMTR studies are asking how treatment can be refined to reduce complications without sacrificing effectiveness.
The OPTIMIZE trial is testing whether lower doses of PTCy can preserve protection against graft-versus-host disease while reducing toxicity and infection burden. Initial reduced-dose results showed favorable infection-free survival, approximately 89% one-year overall survival and low non-relapse mortality. Results from a separate safety cohort also support continued study of intermediate-dose PTCy in patients receiving highly mismatched unrelated donor transplants.
Another analysis found that high exposure to fludarabine was independently associated with greater non-relapse mortality and worse survival. These results support prospective evaluation of personalized, model-informed dosing rather than relying exclusively on conventional dosing approaches.
Two analyses from the GVHD Working Committee explore how evolving GVHD prevention strategies, particularly with PTCy, impact patterns of acute GVHD post-HCT and whether use of mycophenolate mofetil (MMF) enhances GVHD prevention.
Why it matters: These studies move beyond asking whether PTCy-based GVHD prophylaxis works in the HLA matched and mismatched settings. They ask how treatment can be refined for individual patients to reduce infections, toxicity and other complications while maintaining transplant outcomes.
Seeing residual AML more clearly
Four oral presentations from the MEASURE program focus on improving measurable residual disease, or MRD, assessment in acute myeloid leukemia (AML).
MEASURE prospectively validated a whole-genome-informed approach to MRD testing that strongly identified patients at increased risk of relapse. Additional studies evaluated complementary approaches, including a tumor-agnostic blood-based methylation assay and personalized DNA-based testing for KMT2A-altered AML. Both approaches identified residual disease or elevated risk in patients who could be missed by conventional flow cytometry.
A fourth study examined patients treated with hypomethylating agents and venetoclax before transplant. Patients who achieved MRD-negative remission had a low risk of relapse and outcomes comparable with MRD-negative patients treated with intensive chemotherapy, supporting the value of MRD for risk assessment across different treatment strategies.
Why it matters: More sensitive and broadly applicable MRD testing could help clinicians better understand a patient’s risk before transplant and eventually support more individualized treatment and monitoring decisions.
Understanding CAR T in the real world
As CAR T-cell therapy reaches more patients, important questions surface like: How can clinicians better anticipate toxicity? What happens to patients over longer periods of follow-up? And what safety concerns emerge as these therapies are used more broadly?
Four CIBMTR studies at ASH address different pieces of that picture, using registry data to examine prediction of early CAR T-cell toxicity, subsequent primary malignancies after CAR T-cell therapy, and longer-term real-world safety and effectiveness of commercial CAR T-cell therapies - Tisagenlecleucel and lisocabtagene maraleucel.
Why it matters: Longitudinal registry research complements clinical trials by allowing researchers to study patients treated in real-world settings and follow outcomes over time. Together, these studies demonstrate how CIBMTR data can help build a more complete picture of CAR T-cell therapy as its use continues to evolve.
Building evidence where evidence is difficult to generate
Some important questions in hematology are difficult to answer because the conditions being studied are rare or data for specific patient populations are limited. In these settings, bringing together data across institutions in a registry setting, including collaboration across registries, can make it possible.
At ASH, seven related CIBMTR studies examine the role of hematopoietic cell transplantation across rare peripheral T-cell lymphoma subtypes. Another study, conducted jointly by CIBMTR and the European Society for Blood and Marrow Transplantation (EBMT) examines HCT outcomes among patients with Down syndrome-associated AML in the modern era.
Why it matters: These studies demonstrate how CIBMTR’s scale and collaborative research network can help answer important clinical questions that would be difficult for any individual center to study, particularly when available data are limited.
And there’s more
CIBMTR’s presence at ASH extends beyond these featured research themes. Additional presentations examine conditioning approaches for haploidentical HCT, health outcomes among socially vulnerable pediatric transplant recipients, and biomarkers associated with GVHD and mortality. Together, they further illustrate the breadth of questions CIBMTR research is addressing across transplantation and cellular therapy.
A shared accomplishment
This year’s ASH presence reflects the combined contributions of investigators, scientific, statistical, and operational teams, clinical research staff, working committees, participating centers, patients and partners across CIBMTR.
Congratulations to everyone whose work contributed to this outstanding showing and to the presenters who will represent CIBMTR at ASH 2026.
QUICK LINKS BY DATE:
